Radium 223 dichloride for prostate cancer treatment

Abstract : Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01657891
Contributor : Florent Cachin <>
Submitted on : Thursday, December 7, 2017 - 11:11:11 AM
Last modification on : Thursday, February 21, 2019 - 9:56:02 AM

Links full text

Identifiers

Collections

Citation

Emmanuel Deshayes, Mathieu Roumiguié, Constance Thibault, Philippe Beuzeboc, Florent Cachin, et al.. Radium 223 dichloride for prostate cancer treatment. Drug Design, Development and Therapy, Dove Medical Press, 2017, Volume 11, pp.2643 - 2651. ⟨10.2147/DDDT.S122417⟩. ⟨hal-01657891⟩

Share

Metrics

Record views

103